Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Small Molecule Drug Discovery

Published by Global Industry Analysts, Inc. Product code 997559
Published Content info 193 Pages
Delivery time: 1-2 business days
Price
Back to Top
Small Molecule Drug Discovery
Published: April 1, 2021 Content info: 193 Pages
Description

Abstract:

Global Small Molecule Drug Discovery Market to Reach $43.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Small Molecule Drug Discovery estimated at US$30.1 Billion in the year 2020, is projected to reach a revised size of US$43.7 Billion by 2027, growing at a CAGR of 5.5% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$18.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Central Nervous System segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $8.9 Billion, While China is Forecast to Grow at 5% CAGR

The Small Molecule Drug Discovery market in the U.S. is estimated at US$8.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2027 trailing a CAGR of 5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Cardiovascular Segment to Record 5.4% CAGR

In the global Cardiovascular segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$917.5 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5 Billion by the year 2027.

Select Competitors (Total 46 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Table of Contents
Product Code: MCP14780

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Central Nervous System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Immunological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Immunological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Immunological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Target Id/Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Target Id/Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Target Id/Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Hit Generation and Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Hit Generation and Selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Hit Generation and Selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Lead Identification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Lead Identification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Lead Identification by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Lead Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Lead Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Lead Optimization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 34: USA Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 40: Canada Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 46: Japan Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 52: China Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 58: Europe Current & Future Analysis for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 67: France Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: France Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: France 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 70: France Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: France Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: France 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 73: Germany Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Germany Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Germany 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 76: Germany Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Germany Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Germany 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 79: Italy Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Italy Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Italy 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 82: Italy Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Italy Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Italy 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 85: UK Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: UK Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: UK 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 88: UK Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: UK Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: UK 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of Europe Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 97: Asia-Pacific Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 103: Rest of World Current & Future Analysis for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of World Historic Review for Small Molecule Drug Discovery by Therapeutic Area - Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of World 15-Year Perspective for Small Molecule Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System, Cardiovascular, Anti-Infective, Immunological and Other Therapeutic Areas for the Years 2012, 2020 & 2027
    • TABLE 106: Rest of World Current & Future Analysis for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of World Historic Review for Small Molecule Drug Discovery by Process Phase - Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of World 15-Year Perspective for Small Molecule Drug Discovery by Process Phase - Percentage Breakdown of Value Sales for Target Id/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46
Back to Top